Board of directors

Ian Johnson
Executive Chairman

Ian Johnson
Executive Chairman
Ian Johnson was appointed to the Board as Executive Chairman on 5 December 2019.
Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. In addition to his current role as Executive Chairman of NIOX Group plc, Ian is also Senior Independent Director of Induction Healthcare Group plc.
Previous appointments include Executive Chairman of Bioquell PLC, non-executive Chairman of Redcentric plc, Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd., Senior Independent Director of Clinigen plc and Non-Executive Director of Ergomed PLC. He has also served on the boards of various other public and private companies including AIM listed companies; Evans Analytical Group and AOI Medical Inc.
Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a Chartered Biologist, a Fellow of the Royal Society of Biology and a member of the Institute of Directors.

Garry Watts
Senior Independent Director

Garry Watts
Senior Independent Director
Garry Watts was appointed to the Board as a Non-Executive Director and Senior Independent Director on 2 March 2020.
Garry brings to the Company extensive Board-level experience gained in the healthcare sector. He is currently a Non-Executive Director of Coca Cola Europacific Partners plc. He was previously Non-Executive Chairman of Spire Healthcare Group plc, BTG plc, and Foxtons plc, CEO of SSL International plc, Finance Director at Medeva plc and a Director of Celltech Group plc. In addition to his executive roles, Garry was a Non-Executive Director at Protherics plc and a Non-Executive member of the Board of the UK Medicines and Healthcare Regulatory Products Agency for over 15 years.
Garry is a Chartered Accountant and former partner at KPMG and is a member of the Institute of Chartered Accountants in England and Wales.

Michael Roller
Chief Financial Officer

Michael Roller
Chief Financial Officer
Michael Roller was appointed to the Board as Chief Financial Officer on 9 January 2020.
Michael is a highly experienced Finance Director and life sciences company Director. He was previously Group Finance Director of Bioquell PLC, Corin Group PLC and Genus PLC. In addition, Michael has held a number of senior finance roles in a broad range of public and private companies.
Michael completed his training at KPMG and is a Chartered Accountant and member of the ICAEW. He graduated from Merton College, Oxford with a BA in History.

Jonathan Emms
Chief Operating Officer

Jonathan Emms
Chief Operating Officer
Jonathan Emms was appointed to the Board as Chief Operating Officer on 2 September 2019.
Jonathan brings significant senior-level experience of the global pharmaceutical industry to the Group. Previously, he was Chief Commercial Officer for Pfizer’s Internal Medicines organisation, where he led commercial activities across the company’s global operations.
He held a number of senior positions at Pfizer, including Head of Marketing for its Global Established Pharmaceutical Business and Head of Marketing for Specialty Care, Europe, and oversaw the UK launch of Spiriva® under the company’s co-promotion agreement with Boehringer Ingelheim. He was also Country Manager in the UK, Pfizer’s largest affiliate outside the United States, where he had responsibility for manufacturing, research and commercial operations and during his tenure was elected President of the Association of the British Pharmaceutical Industry (ABPI).
Prior to his time at Pfizer, Jonathan held several roles of increasing responsibility at GSK, where he gained significant respiratory experience, including leading the UK launch of Serevent® in COPD. He holds a BSc in Materials Technology from Coventry University, UK.

Jo Le Couilliard
Non-Executive Director

Jo Le Couilliard
Non-Executive Director
Jo LeCouilliard was appointed to the Board as an Independent Non-Executive Director on 8 February 2018.
She has 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernise the commercial model. She was previously Chief Operating Officer at the BMI group of private hospitals in the UK. She was a Non-Executive Director at Frimley Park NHS Foundation Trust in the UK, Cello Health PLC and at the Duke NUS Medical School in Singapore.
Jo is currently a Non-Executive Director at the UK listed companies Alliance Pharma plc and Indivior PLC, and at the Italian listed pharmaceutical company, Recordati S.p.a. She is a graduate of Cambridge University and a Chartered Accountant.

Sharon Curran
Non-Executive Director

Sharon Curran
Non-Executive Director

Nicholas Mills
Non-Executive Director

Nicholas Mills
Non-Executive Director
Nicholas Mills was appointed to the Board as a Non-Independent Non-Executive Director on 13 November 2020.
Nicholas joined Harwood Capital LLP in 2019 after spending 5 years at Gabelli Asset Management in New York and currently acts as a fund manager. At Gabelli, he acted primarily as a Research Analyst covering the multi-industrial space and also gained experience in Merger Arbitrage strategies and marketing Closed End Funds. He has a Bachelor of Science Degree from Boston College’s Carroll School of Management.
He is currently a Non-Executive Director with Trifast plc and Hargreaves Services plc.